Skip to main content

Table 1 Laboratory findings before treatment

From: Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report

Item

Value

Item

Value

Item

Value

AST

51 IU/L

BUN

16 mg/dL

HBsAg

negative

ALT

66 IU/L

Creatinine

0.68 mg/dL

Anti-HCV

positive

LDH

256 IU/L

UA

4.3 mg/dL

HCV RNA

6.4 logIU/mL

ALP

96 IU/L

Na

136 mEq/L

HCV genotype

2b

γ-GTP

88 IU/L

K

3.9 mEq/L

Anti-HIV

negative

T. Bil

1.2 mg/dL

Cl

104 mEq/L

Hyaluronic acid

37 ng/mL

TP

7.1 g/dL

WBC

5900/μL

AFP

7.4 ng/mL

Albumin

3.9 g/dL

RBC

477 × 104/μL

PIVKA-II

32 mAU/mL

Amylase

83 IU/L

Hemoglobin

14.4 g/dL

NH3

58 μg/dL

CPK

102 IU/L

Haematocrit

40.7 %

HbA1c

7.8 %

T.CHO

115 mg/dL

Platelets

15.6 × 104/μL

CRP

0.1 mg/dL

TG

103 mg/dL

PT

100 %

  
  1. AFP α-Fetoprotein, ALP alkaline phosphatase, BUN blood urea nitrogen, CPK creatine phosphokinase, CRP C-reactive protein, HbA1c haemoglobin A1c, LDH lactate dehydrogenase, PIVKA-II protein induced by vitamin K absence or antagonists-II, PT prothrombin time, RBC red blood cell count, T.Bil total bilirubin, T.CHO total cholesterol, TG triglyceride, TP total protein, UA uric acid, WBC white blood cell count